Microparticulate/nanoparticulate powders of a novel Nrf2 activator and an aerosol performance enhancer for pulmonary delivery targeting the lung Nrf2/Keap-1 pathway

Pharmacology, Toxicology and Pharmaceutical Science

• Transcription Factor Nrf2 100%
• Lung Disease 33%
• Acute Lung Injury 33%
• Inflammation 33%
• Chronic Obstructive Lung Disease 33%
• Pulmonary Hypertension 33%
• Nanoparticle 33%
• Microparticle 33%
• Pneumonia 33%
• Endothelial Dysfunction 33%
• Fumaric Acid Dimethyl Ester 33%

Keyphrases

• Drying Parameters 50%
• Endothelial Disease 50%
• High Drug Loading 50%